CONMED
CNMD NYSE· Health Care Equipment
Last close · Oct 23, 2026
$49.25
KIRA · Stoqly’s AI analyst, in plain words
- CONMED had $1.4B of revenue in fiscal 2025, up 5.2% on the year before. Over five years, revenue changed +9.8% a year on average.
- Its operating margin was 7.5%, down 7.9 pts: of every 100 in sales, about 7 is left after running the business.
- CONMED made $47.1M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 12.6% a year.
- Free cash flow was $151M in fiscal 2025, 11.0% of revenue.
- CONMED returned $24.8M to shareholders in fiscal 2025, 16% of free cash flow. The diluted share count rose 0.0%.
- CONMED owes $794M more than it holds in cash, about 5.1 years of operating profit.
Market cap
$1.5B
P/E
—
Revenue
$1.4B
Net income
$47.1M
Free cash flow
$151M
Operating margin
7.5%
CONMED in 30 seconds · fiscal 2025
Are sales growing?
+5.2%
Yes. Sales grew 5.2% last year.
Does it make a profit?
3.4%
A little. It keeps 3.4% of every sale as profit.
Does profit turn into cash?
11.0%
Yes. 11.0% of sales ends up as free cash.
Is debt under control?
5.1x
Heavy. Repaying its debt would take 5.1 years of operating profit.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
What CONMED does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 17, 2026
- Legal name
- CONMED CORPORATION
- CIK
- 0000816956
CONMED · CNMD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.0B | $1.0B | $1.2B | $1.3B | $1.4B |
| Revenue growth | 17.2% | 3.5% | 19.1% | 5.0% | 5.2% |
| Gross margin | 56.2% | 54.6% | 54.3% | 56.1% | 54.6% |
| Operating margin | 10.9% | 6.7% | 9.7% | 15.3% | 7.5% |
| Net income | $62.5M | −$80.6M | $64.5M | $132M | $47.1M |
| Net margin | 6.2% | −7.7% | 5.2% | 10.1% | 3.4% |
| Diluted EPS | $1.94 | −$2.68 | $2.04 | $4.25 | $1.51 |
| Cash | |||||
| Cash from operations | $112M | $33.4M | $125M | $167M | $171M |
| Capital expenditure | $14.9M | $21.8M | $19.0M | $13.1M | $19.8M |
| Free cash flow | $96.9M | $11.6M | $106M | $154M | $151M |
| FCF margin | 9.6% | 1.1% | 8.5% | 11.8% | 11.0% |
| Dividends paid | $23.3M | $24.0M | $24.5M | $24.7M | $24.7M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 9.3% | −6.8% | 5.0% | −1.3% | 0.0% |
| Debt and strength | |||||
| Cash and short-term investments | $20.8M | $28.9M | $24.3M | $24.5M | $40.8M |
| Debt incl. finance leases | $685M | $1.1B | $974M | $906M | $835M |
| Shareholders' equity | $785M | $746M | $834M | $963M | $1.0B |
| Net debt / EBITDA | 4.2x | 8.6x | 5.5x | 3.5x | 5.1x |
| Current ratio | 2.3x | 2.0x | 2.0x | 2.3x | 2.1x |
| Interest coverage | 3.1x | 2.4x | 3.0x | 5.4x | 3.3x |
| Returns and quality | |||||
| Return on capital | 6.5% | 3.4% | 5.4% | 9.0% | 3.7% |
| Return on equity | 8.4% | −10.5% | 8.2% | 14.7% | 4.7% |
| Piotroski F-score | 8 | 4 | 6 | 9 | 6 |
| Altman Z'' | 3.2 | 2.1 | 2.5 | 3.2 | 3.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.2M
2 insiders
Of sales under plans
100%
$0.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
CONMED · CNMD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| CONMED CNMD | $1.5B | 5.2% | 7.5% | 11.0% | 3.7% | — | 6 |
| LivaNova LIVN | $4.6B | 10.7% | 14.4% | 12.5% | 12.8% | 23.9x | 5 |
| Penumbra PEN | $12.8B | 17.5% | 13.5% | 12.5% | 18.8% | 79.7x | 7 |
| Integra Lifesciences IART | $936M | 1.5% | −30.2% | −1.9% | −22.0% | 70.1x | 5 |
| Integer ITGR | $4.3B | 8.0% | 11.9% | 5.7% | 6.6% | 34.7x | 7 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $49.25 a share, the company is worth $1.5B.
CONMED grew sales faster than 1 of its 4 similar companies.
Source: SEC EDGAR XBRL filings (CIK 0000816956). Data updated October 22, 2026. For information only — not investment advice. Check the original filings before relying on any figure.